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Summary.-Tumour-specific antiserum was raised in sheep against idiotypic
determinants on the surface immunoglobulin of neoplastic lymphocytes from a
patient with chronic lymphocytic leukaemia (prolymphocytic variant). The comple-
ment-activating IgG, subclass of the anti-idiotype was prepared from the serum in
monodisperse form for infusion. Two treatments of 480 and 1200 mg caused the
white-cell count to fall by one-third and one-half respectively. However, there was a
rapid resurgence, so that by 8 days after each treatment the counts were restored to
-85°,O, of their former levels. No change was noted in the size of spleen or lymph
nodes. Each treatment probably destroyed4-8 x 101l cells,some1000 ofthetotaltumour
load. The antibody was rapidly consumed, and there was evidence of heavy utilization
of complement.
CERTAIN NEOPLASMS of B lymphocytes
insert immunoglobulin (Ig) molecules into
their surface membranes but do not export
them in amounts sufficient to give detect-
able electrophoretic bands in serum. The
group thus defined includes most cases of
chronic lymphocytic leukaemia (CLL) and
non-Hodgkin lymphoma (Grey et al.,
1971; Leech et al., 1975; Johansson et al.,
1976). Among the antigenic determinants
on this surface Ig are idiotypic deter-
minants, which can be regarded as highly
specialized differentiation antigens. On
individual B lymphocytes all the Ig mole-
cules bear the same idiotypic determin-
ants, but among the total population of
normal B lymphocytes the determinants
present a wide spectrum. When one B
lymphocyte divides to initiate a clone of
cells, normal or neoplastic, the Ig mole-
cules within the clone preserve theparental
idiotypic determinants.
Antibody to the idiotypic determinants
on B lymphocytic neoplasms reacts with
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the neoplastic cells and with only a
negligible proportion of normal lympho-
cytes (Stevenson & Stevenson, 1975;
Hough et al., 1976; Haughton et al., 1978;
Krolick et al., 1979). Raising the antibody
is an individual requirement for each
tumour. Our method involves immunizing
a foreign species, usually sheep, with Fab
liberated from the cell-surface Ig by
limited proteolysis with papain. Six weeks
elapse between receipt of the tumour cells
in the laboratory and provision of the
anti-idiotype.
A therapeutic potential for xenogeneic
anti-idiotype (anti-Id) has been demon-
strated in experimental lymphocytic leu-
kaemias of guinea-pig (Stevenson et al.,
1977b) and mouse (Haughton et al., 1978;
Krolick et al., 1979). Administration of
antibody to animals bearing these fast-
growing tumours has retarded the disease,
and under some circumstances small
tumour loads appear to have been ablated
entirely. In the present paper we recordT. J. HAMBLIN ET AL.
some early observations on the use of
anti-Id in treating a B lymphocytic
leukaemia in man.
PATIENT
C.W., a white male aged 73, was diagnosed
in May 1978 as having CLL with features
characteristic of the prolymphocytic variant
(Galton et al., 1974). On presentation there
was an enlarged left axillary node, spleno-
megaly 6 cm below the costal margin, and a
white-cell count 92 x 109/1 with 99% lympho-
cytes. Serum IgG was 8-7 g/l, IgA 0 3 g/l and
IgM 0-6 g/l, with no monoclonal band appar-
ent. The mean lymphocytic volume (Coulter
Channelyzer) was 340 fl, compared to ranges
of 286-319 fl in 15 normals and 235-280 fl in
10 other cases of CLL. The cell surfaces
exhibited Fcy and C3 receptors, and IgM and
IgD of light-chain class A. On fluorescent
staining the surface Ig was denser than is
usual in CLL. Only 10% ofthe cells, whether
or not pretreated with neuraminidase, formed
rosettes with mouse red cells. Electron
microscopy revealed relatively abundant
cytoplasm and nuclei often blast-like with
prominent nucleoli.
The disease showed steady progression
with the white-cell count doubling over the
next 5 months and the Hb and platelet
levels falling. From December 1978 progres-
sion was retarded by leukaphereses, at first
monthly and then fortnightly, each involving
6 consecutive separations of 600 ml of blood.
By October 1979, immediately before treat-
ment with anti-Id, his Hb was 9-8 g/dl,
white-cell count 256 x 109/1, platelets 95 x
109/1, serum IgG 3-6 g/l, IgA 0 4 g/l, and
IgM 0-1 g/l.
METHODS
Leukaphereses and plasma exchanges were
carried out with a Haemonetics 30 dis-
continuous cell separator.
Antibodies were linked to solid phases by
the CNBr method (Porath et al., 1967): for
immunosorbents, 10 mg IgG to 1 ml packed
Sepharose 4B-CL (Pharmacia); for radio-
immunoassays, 0 4 mg IgG to 1 ml Sephadex
G-25 superfine (Pharmacia).
Anti-Id directed against idiotypic deter-
minants onthe surface IgM ofC.W. leukaemic
cells was prepared by a modification of our
original method (Stevenson & Stevenson,
1975). 4 x 1010 well washed C.W. lymphocytes
from a leukapheretic sample were suspended
in 50 ml of phosphate-buffered saline, pH
7 4, and subjected to limited proteolysis with
papain (0-6 mg/ml, 37TC, 60 min) so as to
cleave the surface IgM in situ and release
Fab,tu into the supernatant (Eady et al., 1974).
The following chromatographic sequence ex-
tracted 50 ,ug of Fab/i from the super-
natant, finally coupling it with sheep anti-
body to its C,PI1 domain to form immunogenic
complexes: (a) preliminary purification ofthe
Fabp, by passage through DEAE-cellulose
(0.06M NaCl, 0.02M Tris-HCl, pH 7.4) and
Sephadex G50; (b) isolation of the Fab,u on
an immunosorbent column, 0-6 x 3 5 cm,
consisting of anti-C,.1 coupled to Sepharose
4B-CL; (c) build-up of immune complexes
on the column by passing through it the same
antibody (anti-CQ1) in the fluid phase; (d)
elution of the Fab,u and fluid-phase anti-
body with 0-5M NH3, 1OM KSCN; (e) imme-
diate transfer of the antigen and antibody
back to neutral buffer by passage through
Sephadex G25. The sequence is carried out in
one automated operation using an 18-outlet,
10-stage sequence controller (Scott Smith
Electronics, Wimborne, Dorset) to actuate
piston pumps (Labotron LDP13, Kontron,
Zurich) and pneumatically activated valves
(Altex Scientific, Berkeley, California). The
immune complexes were used to raise anti-Id
in 2 sheep: primary and booster doses each
contained 5 ,ug of Fab, were given 4 weeks
apart, and each consisted of s.c. injections in
Freund's complete adjuvant in the 4 shanks.
The animals were bled a week later, and 300
ml of antiserum from the better responder
was processed for therapy. Antibody activity
against the constant regions of the Fablu
(anti-C, and anti-CA totalling about 5 mg/
ml) was removed by passing the serum
through an immunosorbent column contain-
ing immobilized human IgMA. The serum
then contained antibody seen by indirect
immunofluorescence to react with the surface
Ig of C.W. lymphocytes, but not with lym-
phocytes from 2 other cases of CLL, nor
with normal lymphocytes.
Antibody-containing IgG was prepared
from anti-Id serum by sequential precipita-
tion with 1-6M (NH4)2SO4 and chromato-
graphy on DEAE-cellulose. To prepare the
IgG2 subclass, the DEAE-cellulose was run
in 0-02M phosphate, pH 7-2; after delivery
of the IgG2, the IgGi subclass was eluted
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With 0-14M NaCi, 0-02M phosphate, pH 7-2.
These IgG fractions all exhibited the same
anti-Id activity as the parent serum. Using
the standard battery of Transfusion Centre
tests they showed no activity against C.W.
red cells nor against a panel of human red
cells.
One-gram lots of monodisperse (i.e. aggre-
gate-free) IgG1 for i.v. infusion were prepared
by passing IgG, obtained as above through
Sephacryl S300 (Pharmacia) equilibrated
with sterile physiological saline. Immediately
before infusion each preparation passed a
pyrogen test in rabbits (European Pharma-
copoeia, 1971).
Solid-phase radioimmunoassays (Eady et
al., 1977) were used to quantify IgM secretion
by C.W. cells, and the level of sheep IgG in
C.W. plasma. For the former assay the
immobilized antibody was sheep purified
anti-C.1, and the radiolabelled antigen
human normal pentameric IgM. For the latter
the immobilized antibody was rabbit purified
anti-sheep Fcy (absorbed with human Ig),
and the radio-labelled antigen, sheep normal
IgGi.
Determinations of lysis of C.W. cells by
antibody and complement were carried out
as described previously (Stevenson et al.,
1977a). Percentages of specific 51Cr-release
were taken as:
Counts released by antibody -
counts released by normal IgG x 100
Counts released bydetergent-
counts released by normal IgG




Access of anti-Id to the patient's cells
would be hampered by any idiotype-
positive Ig secreted by the cells. When
cultured in vitro they were seen to secrete
both IgM and IgD into the supernatant,
the latter at less than 10% the rate of the
former (Fig. 1). Chromatography on
Ultrogel AcA 34 revealed the IgM to be
pentameric. It was also shown to bear the
idiotypic determinants present on the
cell-surface Ig: an immunosorbent pre-
pared with anti-Id bound all the 1gM,
whereas immunosorbent with antibody
against the surface idiotype of another
patient (0. J., also with CLL) bound no
significant amount. The production rate
depicted in Fig. 1 is equivalent to , 300
molecules of pentameric IgM per cell per
hour.
Examination of the patient's serum
revealed that the cells in vivo were also
secreting Ig, but in amounts insufficient
to yield a monoclonal electrophoretic band.
The serum had a total IgM concentration
varying between 0412 and 0-2 mg/ml
(estimated by nephelometry in the Wessex
Regional Immunology Laboratory). Three
samples put through the anti-Id immuno-
sorbent column lost between 54 and 610%
of their IgM content during passage,
whereas normal serum lost less than 10%.
These findings suggest a serum content of
idiotypic IgM between 0-06 and 0412 mg/
ml. By the same investigation the serum
IgD content of 0-017 mg/ml was less than
20% idiotypic.
Time (h)
FIa. 1. Secretion of idiotype-positive IgM
by C. W. cells in vitro. The cells were
suspended in supplemented Eagle's medium
at 2 x 107/ml and swirled gently at 37°C.
At intervals 2ml aliquots were removed,
chilled, and assayed for IgM after removal
of the cells.
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TABLE-Factor in C.W. serum blocking
cell lysis by anti-Id plus complement
% specific
5lCr release
Serum used in presence of
at 1:5 as Blocking
source of factor added Anti- Anti-
complement (final conc.) Id* HLAt
C.W. Nil 7 59
Normal Nil 38 56




1000 250 63 16 4
Immunoglobulin (pg/mi)
FIG. 2.-Lysis ofC. W. cells invitrobyprepara-
tions of IgG from anti-Id serum, plus
human complement. -0- total IgG;
-*- Subclass IgG -A* Subclass
IgG2. The antibody preparations at the
indicated concentrations were incubated
with 5lCr-labelled cells (5 x 105/ml) at 0°C
for 15 min. One-fifth volume of normal
human serum was then added as a source
of complement, the temperature raised
to 37°C, and the release of 51Cr from the
cells measured at 30 min.
IgG prepared from anti-Id serum was
able to kill the leukaemic cells in vitro by
activating human complement (Fig. 2).
Lysis was inhibited completely by the
chelating agent EGTA, indicating that the
complement was being activated via its
classical pathway (Fine et al., 1972). The
minor subclass IgG2 (known to have
little or no complement-activating activity
(Grant et al., 1975; Stevenson & Elliott,
1978)) not only failed to induce killing of
the cells, but appeared also to have block-
ing activity: whole IgG, comprising Sub-
classes 1 and 2, is seen in Fig. 2 to have
been less effective than IgG1 alone in
invoking complement lysis.
In the experiment depicted in the
Table the patient's serum was an ineffec-
tive source ofcomplement for lysisinvoked








* Final concentration 250 Kg/ml of IgG ex
antiserum.
t Decomplemented serum from a multiparous
subject, showing a broad anti-HLA activity; final
concentration 1:10.
another antibody (anti-HLA). This in-
efficiency could have been due to blocking
activity of idiotype-bearing Ig in the
serum; addition of progressively greater
amounts of purified idiotypic IgM to
normal serum progressively lowered the
lysis yielded by that serum in the presence
of anti-Id and, with idiotypic IgM added
to near the concentration present in the
patient's serum, the normal serum became
comparably inefficient in supporting lysis.
Administration of antibody
Two treatments with antibody were
undertaken. The first consisted of a single
infusion; after an interval of 5 weeks the
second consisted of 2 infusions on suc-
cessive days. Three days before each treat-
ment the patient started a course of
allopurinol, 300 mg daily, to prevent
hyperuricaemia. Immediately before each
treatment he was tested for immediate
hypersensitivity to sheep IgGi by a
cutaneous prick test (for IgE-mediated
sensitivity) and by examination of his
serum for precipitins (by micro-Ouchter-
lony technique capable of detecting 5-10
,ug/ml of antibody); these tests were all
negative.
On the morning of 2 October 1979, the
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to lower the circulating concentration of
idiotype-bearing Ig. His plasma was re-
placed by 2-8 1 of plasma-protein fraction
and finally, to help restore complement
levels, by 11 of fresh frozen plasma. Iv.
infusion of 500 ml of physiological saline
containing 800 mg of IgG1 from anti-
idiotype serum was then begun, initially
at 1 1/h. After 250 ml had been given he
became breathless, with evidence of
bronchospasm. The infusion was stopped
and i.v. aminophylline given, whereupon
the bronchospasm rapidly disappeared.
The infusion was re-started cautiously but
was terminated after administration of
480 mg of IgG1 because of recurrence of
the bronchospasm. Thirty min later the
patient had a rigor, his temperature rising
to 38TC. The fever subsided after 6 h with-
out treatment, and there were no other
untoward effects.
On the afternoon of 6 November 1979,
the patient underwent a further 41 plasma
exchange, replacement on this occasion
consisting of 2 1 ofplasma protein fraction
and 2 1 of fresh frozen plasma. 750 mg of
antibody-containing IgG1 in 500 ml of
physiological saline was then infused over
6 h. There was no bronchospasm, but a
rigor occurred 3 h into the infusion, and his
temperature rose to 37-8°C. The infusion
was not interrupted and the pyrexia had
subsided 2 h after its completion. Twenty-
four h later 500 ml of fresh frozen plasma
was infused, followed by a further 420 mg
of IgG1 in 500 ml of physiological saline
given over 6 h. There were no untoward
effects on this occasion. On both of the
next 2 mornings 500 ml of fresh frozen
plasma was infused.
Sequels ofantibody administration
The blood lymphocyte count did not
change significantly after the plasma-
phereses which preceded the antibody
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Days (from 16 July1979)
FIG. 3.- White-cell counts for Patient C.W. over a period of 4 months, showing the responses to
leukaphereses and antibody infusions. Note that the widths of the post-leukaplieresis troughs are
exaggerated by the fact that some 2 weeks usually elapsed before the patient attended for his
next count, whereas counts were carried out daily after the antibody treatments.
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pleting each treatment the first counts
revealed falls, and over the subsequent
36-72 h these falls continued to nadirs of
66% and 50% ofthe pre-treatment counts
for the first and second treatments respec-
tively. The counts then increased, so that
in each case by 8 days after the treatment
they had reached about 85% of their pre-
treatment levels. Throughout this time no
significant changes were detected in neu-
trophil counts or haemoglobin levels. In
Fig. 3 the effects can be compared with
those of therapeutic leukaphereses, with
the reservation that the breadths of the
post-leukapheresis troughs are exaggerated
by the fact that blood counts were not
conducted daily, as they were when assess-
ing antibody treatments. Leukapheresis
was always accompanied by a worrying
reduction (up to 30%) in platelet count,
but there was no reduction after either
antibody treatment.
No change was noted clinically in the
size of spleen or lymph nodes in the week
after either antibody treatment. Nor was
there any significant difference in 4 radio-
isotopic scans of the spleen: before each
treatment, 6 days after the first, and 7
days after the second.
After each treatment there was evidence
of consumption of complement: C3 and
C4 levels, already diminished by plasma
exchange, fell further, and were slow to
recover. The complement conversion pro-
duct 03c was detected in the patient's
plasma 18 h after the first treatment, and
in smaller amount 9 h after the second
infusion of the second treatment (Strong
& Watkins, 1979).
Between 1 and 6 days after each treat-
ment the level of sheep IgG, in the
patient's plasma was monitored by radio-
immunoassay. It fell exponentially, with
half-lives of 5.0 days and 5-1 days on the
2 occasions. However, the anti-idiotype
component ofthe IgG, probably fell much
more rapidly: 16 h after the second treat-
ment, when the concentration of sheep
IgG, in the plasma suggested a concentra-
tion of anti-idiotype adequate for coating
idiotype-bearing cells, examination of the
blood lymphocytes by indirect immuno-
fluorescence revealed no such coating.
Its absence could not be explained by
internalization of antigen antibody com-
plexes from the cell surface, because
examination with anti-Igreagentsrevealed
the surface Ig in normal amount and
distribution.
DISCUSSION
It has long been known that antibodies
are capable of killing leukaemic cells
(Gorer, 1942) and more recent evidence
(Proctor et al., 1973) suggests that they
can ablate micrometastases. The presence
on B-lymphocytic neoplasms of Ig idio-
types, about which a great deal is known
at the molecular level (Capra & Kehoe,
1975) offers in anti-Id an opportunity for
studying the preparation and action of
tumour-specific antibody with some pre-
cision. The system has the disadvantage
of requiring the raising of a different anti-
body for each tumour, but the idiotypic
determinants appear to be reliably strong
immunogens. Some therapeutic activity
of anti-Id has been demonstrated in
animals (Stevenson etal., 1977b; Haughton
et al., 1978; Krolick et al., 1979) although
the malignancy of the experimental
tumours renders extrapolation to man
uncertain. The patient described in the
present report had a rapidly advancing
leukaemia not subjected to chemotherapy
(the prolymphocytic variant characteris-
tically responds poorly to such treatment
(Galton et al., 1974)) and so offered an
excellent opportunity for preliminary
evaluation of the antibody in man.
At this early stage some of our strategy
(choice of the IgGi subclass and supple-
mentation of the patient's complement) is
based on the assumption that the major
killing agent to be invoked bythe antibody
will be complement, the activation of
which at the cell surface can lead to lysis
and opsonization. A limited amount of
evidence available from animal work
supports this assumption (Kassell et al.,
1973; Bernstein et at., 1980). Other pos-
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sible anti-tumour mechanisms operative
through antibody include simple meta-
bolic perturbation (Virji & Stevenson,
1979) complement-independent opsoniza-
tion (Fakhri et al., 1973) and K-cell lysis
(MacLennan, 1972). In sheep antibodies,
K-cell lysis is promoted by the IgG2
subclass (Stevenson & Elliott, 1978) which
was removed from our preparation be-
cause of its blocking activity for comple-
mentlysis.
Antibody was given i.v. in order to
avoid the pain associated with large i.m.
injections of IgG, and because i.v. non-
aggregated antigen frequently induces
tolerance rather than immunization (Dres-
ser, 1962). The first reaction observed in
our patient, bronchospasm, was not seen
during the second and third infusions,
which were given at a much slower rate
than the first. It possibly arose from the
action of anaphylatoxins, C3a and C5a
(Hugli & Miiller-Eberhard, 1978) released
when antibody-antigen reactions acti-
vated complement; a reaginic mechanism
is unlikely in view of the repeated failure
of sheep IgG to give a skin reaction. The
pyrexia observed some hours after the
start of the first and second infusions was
surprising in view of the steps taken to
exclude pyrogens from the antibody
preparations. Possibly it arose from wide-
spread phagocytosis by neutrophils, which
promoted a slow release of endogenous
pyrogen (Berlin & Wood, 1964).
A proportion of the patient's leukaemic
cells appear to have been selectively killed
by anti-Id with no effects on neutrophil
or platelet counts. Simple calculations
based on the post-treatment falls in blood
lymphocyte counts (assuming a blood
volume of 5 1) suggest that the single
infusion of the first treatment removed
4 x 1011 cells, and that the 2 infusions
of the second treatment removed 8 x 1011
cells. These amounts are comparable with
those removed by large leukaphereses.
Some lysis is presumed to have occurred,
and phagocytosis of opsonized cells and
cellular debris may have proceeded over
2-3 days. In view of the very rapid
consumption of antibody we assume that
there can have been little depletion of
extravascular lymphocytes. The estimates
of cells removed might be low, due to
replenishment of the vascular compart-
ment while the count was falling, or might
be high, due to an unexplained migration
ofcells from the blood.
The rapid resurgence of the blood
lymphocyte count after leukapheretic or
immunological depletion is consistent with
the existence of a large readily accessible
pool of tissue CLL cells (Manaster et al.,
1973; Theml et al., 1973). However, some
CLL cells in tissues (and apparently in
the marrow particularly (Theml et al.,
1973; Scott et al., 1973)) exchange poorly
with the blood, so it has proved difficult to
assess the sizes of the various cellular
compartments of this neoplasm. In our
patient, with only modest splenomegaly
and lymphadenopathy, it seems likely
that the tumour burden in the blood at the
time of study (- 1.5 x 1012 cells) represen-
ted at least 20-30% of the total. On this
basis the reduction in blood count after
each treatment represented on average a
removal ofsome 10O% ofthe totaltumour.
These preliminary results demonstrate
that anti-Id is by itself capable of limited
killing of Ig-bearing neoplastic lympho-
cytes, possibly via the activation of com-
plement. Elaborations of its use which
might be envisaged include combination
with cytotoxic therapy, linkage to toxin
or radioisotope, or clearance of idiotype-
bearing tumour cells from autologous
marrow destined for re-implantation.
We are indebted to Dr D. Catovsky for reporting
on the rosetting characteristics of C. W. cells, to
the Wessex Regional Transfusion Centre for checking
our antibody preparations for activity against red
cells, and to the Department of Nuclear Medicine,
Southampton General Hospital, for carrying out
99Tcm sulphur-colloid imaging of spleen and liver.
This work has been supported by the Medical
Research Council, the Cancer Research Campaign,
Tenovus, andthe WessexRegional Health Authority.
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